[{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"ATI-2307","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATI-2307","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Appili Therapeutics \/ Appili Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Appili Therapeutics"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"Appili Therapeutics \/ CATO Research","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ CATO Research"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"tablet","sponsorNew":"Appili Therapeutics \/ Appili Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Appili Therapeutics"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Global Fund II, LP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Lind Global Fund II, LP","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Lind Global Fund II, LP"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ FUJIFILM Toyama Chemical","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ FUJIFILM Toyama Chemical"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"AiPharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Appili","highestDevelopmentStatusID":"11","companyTruncated":"Appili Therapeutics \/ Appili"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities Inc."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"ATI-2307","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Appili Therapeutics \/ The Lind Partners","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ The Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Saptalis"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Long Zone Holdings Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-2307","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Long Zone Holdings Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Long Zone Holdings Inc."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Air Force Academy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ U.S. Air Force Academy","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ U.S. Air Force Academy"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis pharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis pharm","highestDevelopmentStatusID":"12","companyTruncated":"Appili Therapeutics \/ Saptalis pharm"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"USAFA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ USAFA","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ USAFA"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ATI-1701","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Appili Therapeutics \/ Aditxt"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"ATI-1701","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"14","companyTruncated":"Appili Therapeutics \/ Aditxt"}]
Find Clinical Drug Pipeline Developments & Deals by Appili Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
